Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine

M. Shibasaki, S. L. Davis, J. Cui, D. A. Low, D. M. Keller, C. G. Crandall

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Botulinum toxin A (BTX) disrupts neurotransmitter release from cholinergic nerves. The effective duration of impaired sweat secretion with BTX is longer relative to that of impaired muscle contraction, suggesting different mechanisms in these tissues. Objectives The aim of this study was to test the hypothesis that BTX is capable of altering sweating by reducing the responsiveness of the sweat gland to acetylcholine. Methods BTX was injected into the dorsal forearm skin of healthy subjects at least 3 days before subsequent assessment. On the day of the experiment, intradermal microdialysis probes were placed within the BTX-treated area and in an adjacent untreated area. Incremental doses of acetylcholine were administered through the microdialysis membranes while the sweat rate (protocol 1; n = 8) or a combination of sweat rate and skin blood flow (protocol 2; n = 8) were assessed. Results A relative absence of sweating was observed at the BTX site for both protocols (protocol 1: 0·05 ± 0·09 mg cm-2 min-1; protocol 2: 0·03 ± 0·04 mg cm -2 min-1, both at the highest dose of acetylcholine), while the sweat rate increased appropriately at the control sites (protocol 1: 0·90 ± 0·46 mg cm-2 min-1; protocol 2: 1·07 ± 0·67 mg cm-2 min-1). Cutaneous vascular conductance increased to a similar level at both the BTX and control sites. Conclusions These results demonstrate that BTX is capable of inhibiting sweat secretion by reducing the responsiveness of the sweat gland to acetylcholine, while not altering acetylcholine-mediated cutaneous vasodilatation.

Original languageEnglish (US)
Pages (from-to)757-761
Number of pages5
JournalBritish Journal of Dermatology
Volume161
Issue number4
DOIs
StatePublished - Oct 2009

Fingerprint

Sweat Glands
Type A Botulinum Toxins
Sweating
Botulinum Toxins
Acetylcholine
Sweat
Skin
Microdialysis
Muscle Contraction
Forearm
Vasodilation
Cholinergic Agents
Neurotransmitter Agents
Blood Vessels
Healthy Volunteers
Membranes

Keywords

  • Acetylcholine
  • Cholinergic nerve
  • Muscarinic receptor
  • Skin blood flow
  • Sweat rate

ASJC Scopus subject areas

  • Dermatology

Cite this

Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine. / Shibasaki, M.; Davis, S. L.; Cui, J.; Low, D. A.; Keller, D. M.; Crandall, C. G.

In: British Journal of Dermatology, Vol. 161, No. 4, 10.2009, p. 757-761.

Research output: Contribution to journalArticle

Shibasaki, M. ; Davis, S. L. ; Cui, J. ; Low, D. A. ; Keller, D. M. ; Crandall, C. G. / Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine. In: British Journal of Dermatology. 2009 ; Vol. 161, No. 4. pp. 757-761.
@article{98c41364fbc144eab7b0482550c06da5,
title = "Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine",
abstract = "Background Botulinum toxin A (BTX) disrupts neurotransmitter release from cholinergic nerves. The effective duration of impaired sweat secretion with BTX is longer relative to that of impaired muscle contraction, suggesting different mechanisms in these tissues. Objectives The aim of this study was to test the hypothesis that BTX is capable of altering sweating by reducing the responsiveness of the sweat gland to acetylcholine. Methods BTX was injected into the dorsal forearm skin of healthy subjects at least 3 days before subsequent assessment. On the day of the experiment, intradermal microdialysis probes were placed within the BTX-treated area and in an adjacent untreated area. Incremental doses of acetylcholine were administered through the microdialysis membranes while the sweat rate (protocol 1; n = 8) or a combination of sweat rate and skin blood flow (protocol 2; n = 8) were assessed. Results A relative absence of sweating was observed at the BTX site for both protocols (protocol 1: 0·05 ± 0·09 mg cm-2 min-1; protocol 2: 0·03 ± 0·04 mg cm -2 min-1, both at the highest dose of acetylcholine), while the sweat rate increased appropriately at the control sites (protocol 1: 0·90 ± 0·46 mg cm-2 min-1; protocol 2: 1·07 ± 0·67 mg cm-2 min-1). Cutaneous vascular conductance increased to a similar level at both the BTX and control sites. Conclusions These results demonstrate that BTX is capable of inhibiting sweat secretion by reducing the responsiveness of the sweat gland to acetylcholine, while not altering acetylcholine-mediated cutaneous vasodilatation.",
keywords = "Acetylcholine, Cholinergic nerve, Muscarinic receptor, Skin blood flow, Sweat rate",
author = "M. Shibasaki and Davis, {S. L.} and J. Cui and Low, {D. A.} and Keller, {D. M.} and Crandall, {C. G.}",
year = "2009",
month = "10",
doi = "10.1111/j.1365-2133.2009.09248.x",
language = "English (US)",
volume = "161",
pages = "757--761",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine

AU - Shibasaki, M.

AU - Davis, S. L.

AU - Cui, J.

AU - Low, D. A.

AU - Keller, D. M.

AU - Crandall, C. G.

PY - 2009/10

Y1 - 2009/10

N2 - Background Botulinum toxin A (BTX) disrupts neurotransmitter release from cholinergic nerves. The effective duration of impaired sweat secretion with BTX is longer relative to that of impaired muscle contraction, suggesting different mechanisms in these tissues. Objectives The aim of this study was to test the hypothesis that BTX is capable of altering sweating by reducing the responsiveness of the sweat gland to acetylcholine. Methods BTX was injected into the dorsal forearm skin of healthy subjects at least 3 days before subsequent assessment. On the day of the experiment, intradermal microdialysis probes were placed within the BTX-treated area and in an adjacent untreated area. Incremental doses of acetylcholine were administered through the microdialysis membranes while the sweat rate (protocol 1; n = 8) or a combination of sweat rate and skin blood flow (protocol 2; n = 8) were assessed. Results A relative absence of sweating was observed at the BTX site for both protocols (protocol 1: 0·05 ± 0·09 mg cm-2 min-1; protocol 2: 0·03 ± 0·04 mg cm -2 min-1, both at the highest dose of acetylcholine), while the sweat rate increased appropriately at the control sites (protocol 1: 0·90 ± 0·46 mg cm-2 min-1; protocol 2: 1·07 ± 0·67 mg cm-2 min-1). Cutaneous vascular conductance increased to a similar level at both the BTX and control sites. Conclusions These results demonstrate that BTX is capable of inhibiting sweat secretion by reducing the responsiveness of the sweat gland to acetylcholine, while not altering acetylcholine-mediated cutaneous vasodilatation.

AB - Background Botulinum toxin A (BTX) disrupts neurotransmitter release from cholinergic nerves. The effective duration of impaired sweat secretion with BTX is longer relative to that of impaired muscle contraction, suggesting different mechanisms in these tissues. Objectives The aim of this study was to test the hypothesis that BTX is capable of altering sweating by reducing the responsiveness of the sweat gland to acetylcholine. Methods BTX was injected into the dorsal forearm skin of healthy subjects at least 3 days before subsequent assessment. On the day of the experiment, intradermal microdialysis probes were placed within the BTX-treated area and in an adjacent untreated area. Incremental doses of acetylcholine were administered through the microdialysis membranes while the sweat rate (protocol 1; n = 8) or a combination of sweat rate and skin blood flow (protocol 2; n = 8) were assessed. Results A relative absence of sweating was observed at the BTX site for both protocols (protocol 1: 0·05 ± 0·09 mg cm-2 min-1; protocol 2: 0·03 ± 0·04 mg cm -2 min-1, both at the highest dose of acetylcholine), while the sweat rate increased appropriately at the control sites (protocol 1: 0·90 ± 0·46 mg cm-2 min-1; protocol 2: 1·07 ± 0·67 mg cm-2 min-1). Cutaneous vascular conductance increased to a similar level at both the BTX and control sites. Conclusions These results demonstrate that BTX is capable of inhibiting sweat secretion by reducing the responsiveness of the sweat gland to acetylcholine, while not altering acetylcholine-mediated cutaneous vasodilatation.

KW - Acetylcholine

KW - Cholinergic nerve

KW - Muscarinic receptor

KW - Skin blood flow

KW - Sweat rate

UR - http://www.scopus.com/inward/record.url?scp=70349345904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349345904&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2009.09248.x

DO - 10.1111/j.1365-2133.2009.09248.x

M3 - Article

C2 - 19538183

AN - SCOPUS:70349345904

VL - 161

SP - 757

EP - 761

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 4

ER -